

# Jashvant D Unadkat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4703625/publications.pdf>

Version: 2024-02-01

207  
papers

10,966  
citations

21215

62  
h-index

48101

92  
g-index

211  
all docs

211  
docs citations

211  
times ranked

8705  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. <i>Clinical and Translational Science</i> , 2022, 15, 322-329.	1.5	3
2	Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 593-604.	2.3	3
3	Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2022, 50, 351-360.	1.7	25
4	Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model. <i>Drug Metabolism and Disposition</i> , 2022, 50, 613-623.	1.7	7
5	Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model. <i>Drug Metabolism and Disposition</i> , 2022, 50, 519-528.	1.7	3
6	Characterizing and Quantifying Extrahepatic Metabolism of ( $\Delta^9$ )-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, ( $\Delta^9$ )-11-Hydroxy-THC (11-OH-THC). <i>Drug Metabolism and Disposition</i> , 2022, 50, 734-740.	1.7	7
7	Is the Protein-Mediated Uptake of Drugs by Organic Anion Transporting Polypeptides a Real Phenomenon or an Artifact?. <i>Drug Metabolism and Disposition</i> , 2022, 50, 1132-1141.	1.7	6
8	Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. <i>Pharmaceutical Research</i> , 2022, 39, 1701-1731.	1.7	40
9	Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. <i>Drug Metabolism and Disposition</i> , 2021, 49, 159-168.	1.7	24
10	Assessing Transporter-Mediated Natural Product-Drug Interactions Via <i>In vitro</i> - <i>In Vivo</i> Extrapolation: Clinical Evaluation With a Probe Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1342-1352.	2.3	21
11	Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 667-675.	2.3	35
12	Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. <i>Pharmacological Reviews</i> , 2021, 73, 847-859.	7.1	8
13	<i>In vitro</i> - <i>In Vivo</i> Extrapolation of Transporter-Mediated Renal Clearance: Relative Expression Factor Versus Relative Activity Factor Approach. <i>Drug Metabolism and Disposition</i> , 2021, 49, 470-478.	1.7	17
14	Can Cannabinoids Precipitate UGT-Mediated Drug Interactions?. <i>FASEB Journal</i> , 2021, 35, .	0.2	2
15	Abundance of P-glycoprotein and Breast Cancer Resistance Protein Measured by Targeted Proteomics in Human Epileptogenic Brain Tissue. <i>Molecular Pharmaceutics</i> , 2021, 18, 2263-2273.	2.3	11
16	Successful Prediction of Human Steady-State Unbound Brain-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 432-442.	2.3	18
17	Development and verification of a linked $\Delta^9$ -THC/11-OH-THC physiologically-based pharmacokinetic (PBPK) model in healthy, non-pregnant population and extrapolation to pregnant women. <i>Drug Metabolism and Disposition</i> , 2021, 49, DMD-AR-2020-000322.	1.7	12
18	Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1057-1070.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2). Drug Metabolism and Disposition, 2021, 49, 910-918.	1.7	6
20	Prediction of pregnancy-induced changes in secretory and total renal clearance of drugs transported by organic anion transporters. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2021-000557.	1.7	9
21	Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation. Drug Metabolism and Disposition, 2021, 49, 919-928.	1.7	25
22	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2020, 107, 96-101.	2.3	6
23	Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics. Drug Metabolism and Disposition, 2020, 48, 735-741.	1.7	53
24	Successful Prediction of Positron Emission Tomography-Imaged Metformin Hepatic Uptake Clearance in Humans Using the Quantitative Proteomics-Informed Relative Expression Factor Approach. Drug Metabolism and Disposition, 2020, 48, 1210-1216.	1.7	15
25	Pitfalls in Predicting Hepatobiliary Drug Transport Using Human Sandwich-Cultured Hepatocytes. AAPS Journal, 2020, 22, 110.	2.2	7
26	Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. Drug Metabolism and Disposition, 2020, 48, 1008-1017.	1.7	50
27	Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples. AAPS Journal, 2019, 21, 88.	2.2	33
28	Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical Pharmacology and Therapeutics, 2019, 106, 228-237.	2.3	64
29	Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper. Clinical Pharmacology and Therapeutics, 2019, 106, 525-543.	2.3	77
30	Positron Emission Tomography Imaging of [ <sup>11</sup> C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. Clinical Pharmacology and Therapeutics, 2019, 106, 1056-1066.	2.3	51
31	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. , 2019, 201, 25-38.		65
32	Quantifying Hepatic Enzyme Kinetics of (-)- <sup>9</sup> -Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. Drug Metabolism and Disposition, 2019, 47, 743-752.	1.7	18
33	Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells. AAPS Journal, 2019, 21, 45.	2.2	15
34	Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. Drug Metabolism and Disposition, 2019, 47, 1122-1135.	1.7	79
35	Hepatic Enzymes Relevant to the Disposition of ( <sup>9</sup> -)-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. Drug Metabolism and Disposition, 2019, 47, 249-256.	1.7	23
36	Organic anion transporting polypeptide 2B1 - More than a glass-full of drug interactions. , 2019, 196, 204-215.		45

#	ARTICLE	IF	CITATIONS
37	A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 350-357.	1.7	37
38	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	1.7	43
39	Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. <i>Drug Metabolism and Disposition</i> , 2018, 46, 943-952.	1.7	74
40	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. <i>Molecular Pharmacology</i> , 2018, 94, 689-699.	1.0	40
41	Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 66-74.	1.7	40
42	Targeted LC-MS/MS Proteomics-Based Strategy To Characterize in Vitro Models Used in Drug Metabolism and Transport Studies. <i>Analytical Chemistry</i> , 2018, 90, 11873-11882.	3.2	26
43	When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1487-1496.	1.7	11
44	Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1251-1258.	1.7	14
45	Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>in Vitro</i> , Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 865-889.	2.3	92
46	The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in <i>in Vivo</i> of Metformin Renal Secretory Clearance. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1441-1445.	1.7	38
47	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 890-899.	2.3	185
48	Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1046-1052.	1.7	19
49	Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs. <i>Drug Metabolism and Disposition</i> , 2017, 45, 939-946.	1.7	75
50	Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses. <i>Drug Metabolism and Disposition</i> , 2017, 45, 920-938.	1.7	74
51	Optimization and Application of a Biotinylation Method for Quantification of Plasma Membrane Expression of Transporters in Cells. <i>AAPS Journal</i> , 2017, 19, 1377-1386.	2.2	20
52	Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 362-370.	2.3	122
53	CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids. <i>Drug Metabolism and Disposition</i> , 2016, 44, 750-757.	1.7	26
54	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1752-1758.	1.7	100

#	ARTICLE	IF	CITATIONS
55	Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1920-1924.	1.7	114
56	Placental ABC Transporters: Biological Impact and Pharmaceutical Significance. <i>Pharmaceutical Research</i> , 2016, 33, 2847-2878.	1.7	84
57	Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 413-418.	2.3	79
58	The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 336-344.	1.1	10
59	Quantitative Transporter Proteomics by Liquid Chromatography with Tandem Mass Spectrometry: Addressing Methodologic Issues of Plasma Membrane Isolation and Expression-Activity Relationship. <i>Drug Metabolism and Disposition</i> , 2015, 43, 284-288.	1.7	44
60	Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2â€™ Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1008-1018.	1.7	39
61	The concept of fraction of drug transported ( $f_{t}$ ) with special emphasis on BBB efflux of CNS and antiretroviral drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 320-323.	2.3	16
62	Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2015, 43, 367-374.	1.7	152
63	Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1795-1804.	1.7	37
64	Prediction of Gestational Ageâ€™Dependent Induction of In Vivo Hepatic CYP3A Activity Based on HepaRG Cells and Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2015, 43, 836-842.	1.7	28
65	Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transportâ€™an Update. <i>AAPS Journal</i> , 2015, 17, 65-82.	2.2	463
66	Comparison of Heavy Labeled (SIL) Peptide versus SILAC Protein Internal Standards for LC-MS/MS Quantification of Hepatic Drug Transporters. <i>International Journal of Proteomics</i> , 2014, 2014, 1-11.	2.0	16
67	Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitorâ€™Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells. <i>Drug Metabolism and Disposition</i> , 2014, 42, 162-171.	1.7	40
68	Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1301-1313.	1.7	31
69	Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 554-570.	1.1	91
70	Mechanism of an unusual, but clinically significant, digoxinâ€™bupropion drug interaction. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 253-263.	1.1	16
71	Role of (Drug) Transporters in Imaging in Health and Disease. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2007-2015.	1.7	11
72	Identification of CYP3A7 for glyburide metabolism in human fetal livers. <i>Biochemical Pharmacology</i> , 2014, 92, 690-700.	2.0	28

#	ARTICLE	IF	CITATIONS
73	Pharmacometrics in Pregnancy: An Unmet Need. Annual Review of Pharmacology and Toxicology, 2014, 54, 53-69.	4.2	76
74	Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex. Drug Metabolism and Disposition, 2014, 42, 78-88.	1.7	169
75	Predicting the Outer Boundaries of P-glycoprotein (P-gp)-Based Drug Interactions at the Human Blood-Brain Barrier Based on Rat Studies. Molecular Pharmaceutics, 2014, 11, 436-444.	2.3	14
76	Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine. Molecular Pharmaceutics, 2014, 11, 3547-3555.	2.3	211
77	Activity of P-Glycoprotein, a $\beta$ -Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. Journal of Nuclear Medicine, 2014, 55, 1106-1111.	2.8	156
78	Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochemical Pharmacology, 2014, 91, 109-118.	2.0	38
79	PET Imaging of Oatp-Mediated Hepatobiliary Transport of [ <sup>11</sup> C] Rosuvastatin in the Rat. Molecular Pharmaceutics, 2014, 11, 2745-2754.	2.3	47
80	Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics. AAPS Journal, 2014, 16, 634-648.	2.2	90
81	Cytochrome P450-Dependent Catabolism of Vitamin K: $\alpha$ -Hydroxylation Catalyzed by Human CYP4F2 and CYP4F11. Biochemistry, 2013, 52, 8276-8285.	1.2	72
82	Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, <sup>11</sup> C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman Primate: Impact of Tissue Blood Flow and Site of Inhibition. Journal of Nuclear Medicine, 2013, 54, 437-446.	2.8	29
83	Effect of Salt Intake on Bioavailability of Mizoribine in Healthy Japanese Males. Drug Metabolism and Pharmacokinetics, 2013, 28, 75-80.	1.1	7
84	Effect of Gestational Age on mRNA and Protein Expression of Polyspecific Organic Cation Transporters during Pregnancy. Drug Metabolism and Disposition, 2013, 41, 2225-2232.	1.7	53
85	Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs. Biopharmaceutics and Drug Disposition, 2013, 34, 155-164.	1.1	9
86	Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype. Journal of Pharmaceutical Sciences, 2013, 102, 787-793.	1.6	99
87	A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women. Drug Metabolism and Disposition, 2013, 41, 801-813.	1.7	78
88	Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell Lines. Drug Metabolism and Disposition, 2013, 41, 281-290.	1.7	51
89	Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin, or Bupropion. Drug Metabolism and Disposition, 2012, 40, 610-616.	1.7	39
90	Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2012, 40, 852-855.	1.7	79

#	ARTICLE	IF	CITATIONS
91	Role of the Equilibrative and Concentrative Nucleoside Transporters in the Intestinal Absorption of the Nucleoside Drug, Ribavirin, in Wild-Type and Ent1(â™/â™) Mice. <i>Molecular Pharmaceutics</i> , 2012, 9, 2442-2449.	2.3	21
92	P-Glycoprotein-Based Loperamideâ€“Cyclosporine Drug Interaction at the Rat Bloodâ€“Brain Barrier: Prediction from <i>In Vitro</i> Studies and Extrapolation to Humans. <i>Molecular Pharmaceutics</i> , 2012, 9, 629-633.	2.3	25
93	Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LCâ€“MS/MS cocktail assays and RTâ€“PCR. <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 207-217.	1.1	19
94	Substrate- and Species-dependent Inhibition of P-glycoprotein-mediated Transport: Implications for Predicting <i>in vivo</i> Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3055-3061.	1.6	43
95	Complex Drug Interactions of HIV Protease Inhibitors 2: <i>In Vivo</i> Induction and <i>In Vitro</i> to <i>In Vivo</i> Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2329-2337.	1.7	62
96	Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1070-1078.	1.7	96
97	Contributions of human cytochrome P450 enzymes to glyburide metabolism. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 228-242.	1.1	51
98	Positron emission tomography imaging of tissue Pâ€“glycoprotein activity during pregnancy in the nonâ€“human primate. <i>British Journal of Pharmacology</i> , 2010, 159, 394-404.	2.7	33
99	Different Modes of Transport for <sup>3</sup> H-Thymidine, <sup>3</sup> H-FLT, and <sup>3</sup> H-FMAU in Proliferating and Nonproliferating Human Tumor Cells. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1464-1471.	2.8	37
100	Increased Glyburide Clearance in the Pregnant Mouse Model. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1403-1406.	1.7	15
101	Human Equilibrative Nucleoside Transporter-3 (hENT3) Spectrum Disorder Mutations Impair Nucleoside Transport, Protein Localization, and Stability. <i>Journal of Biological Chemistry</i> , 2010, 285, 28343-28352.	1.6	76
102	Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass Contribution. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1926-1933.	1.7	25
103	Testicular Expression of Adora3i2 in Adora3 Knockout Mice Reveals a Role of Mouse A3Ri2 and Human A3Ri3 Adenosine Receptors in Sperm*. <i>Journal of Biological Chemistry</i> , 2010, 285, 33662-33670.	1.6	24
104	The Impact and <i>In Vitro</i> to <i>In Vivo</i> Prediction of Transporter-Based Drugâ€“Drug Interactions in Humans. , 2010, , 517-553.		4
105	The Role of Nucleoside Transporters in the Erythrocyte Disposition and Oral Absorption of Ribavirin in the Wild-Type and Equilibrative Nucleoside Transporter 1(â™/â™) Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 287-296.	1.3	32
106	The Role of the Equilibrative Nucleoside Transporter 1 (ENT1) in Transport and Metabolism of Ribavirin by Human and Wild-Type or Ent1(-/-) Mouse Erythrocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 387-398.	1.3	57
107	As in Humans, Pregnancy Increases the Clearance of the Protease Inhibitor Nelfinavir in the Nonhuman Primate <i>Macaca nemestrina</i> . <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 1016-1022.	1.3	2
108	Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using <sup>11</sup> C-Verapamil in the Brain: Studies of Healthy Humans. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1267-1275.	2.8	127

#	ARTICLE	IF	CITATIONS
109	Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 798-806.	2.8	47
110	Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G910-G922.	1.6	120
111	Pregnancy Does Not Increase CYP3A or P-Glycoprotein Activity in the Non-Human Primate, <i>Macaca nemestrina</i> . <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 586-595.	1.3	4
112	Drug interactions at the blood-brain barrier: Fact or fantasy? <i>Pharmacology and Therapeutics</i> , 2009, 123, 80-104.		173
113	Effect of Pregnancy on Nitrofurantoin Disposition in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4306-4315.	1.6	4
114	Interplay of Drug Metabolism and Transport: A Real Phenomenon or an Artifact of the Site of Measurement? <i>Molecular Pharmaceutics</i> , 2009, 6, 1756-1765.	2.3	22
115	Hormonal Regulation of BCRP Expression in Human Placental BeWo Cells. <i>Pharmaceutical Research</i> , 2008, 25, 444-452.	1.7	43
116	Sensitive and specific LC-MS assay for quantification of digoxin in human plasma and urine. <i>Biomedical Chromatography</i> , 2008, 22, 712-718.	0.8	24
117	Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. <i>Biochemical Pharmacology</i> , 2008, 75, 1677-1687.	2.0	30
118	Rapid solid-phase extraction method to quantify [11C]-verapamil, and its [11C]-metabolites, in human and macaque plasma. <i>Nuclear Medicine and Biology</i> , 2008, 35, 911-917.	0.3	15
119	The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. <i>Molecular Pharmacology</i> , 2008, 73, 949-959.	1.0	99
120	In Vitro-to-in Vivo Prediction of P-glycoprotein-Based Drug Interactions at the Human and Rodent Blood-Brain Barrier. <i>Drug Metabolism and Disposition</i> , 2008, 36, 481-484.	1.7	63
121	Effect of Pregnancy on Cytochrome P450 3a and P-Glycoprotein Expression and Activity in the Mouse: Mechanisms, Tissue Specificity, and Time Course. <i>Molecular Pharmacology</i> , 2008, 74, 714-723.	1.0	81
122	Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells. <i>Molecular Pharmacology</i> , 2008, 73, 845-854.	1.0	104
123	New insights into the pharmacology and cytotoxicity of gemcitabine and 2â€²,2â€²-difluorodeoxyuridine. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2415-2425.	1.9	85
124	Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1172-1180.	1.7	102
125	Profiling Gene Expression in Human Placentae of Different Gestational Ages: An OPRU Network and UW SCOR Study. <i>Reproductive Sciences</i> , 2008, 15, 866-877.	1.1	121
126	Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G570-G580.	1.6	61



#	ARTICLE	IF	CITATIONS
127	Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 783-786.	1.4	75
128	Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1853-1859.	1.7	126
129	Inhibition of P-glycoprotein Activity at the Primate Blood-Brain Barrier Increases the Distribution of Nelfinavir into the Brain but Not into the Cerebrospinal Fluid. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1459-1462.	1.7	58
130	In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R1809-R1822.	0.9	126
131	Breast Cancer Resistance Protein 1 Limits Fetal Distribution of Nitrofurantoin in the Pregnant Mouse. <i>Drug Metabolism and Disposition</i> , 2007, 35, 2154-2158.	1.7	73
132	In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 257-262.	1.1	59
133	Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 3226-3235.	1.6	71
134	Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: An OPRU Network study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 860, 34-41.	1.2	20
135	Grapefruit Juice, a Glass Full of Drug Interactions?. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 631-633.	2.3	38
136	Simultaneous Measurement of In Vivo P-glycoprotein and Cytochrome P450 3A Activities. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1313-1319.	1.0	33
137	Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 704-710.	1.3	87
138	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 374-383.	1.1	103
139	The role of transporters in drug interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 501-517.	1.9	178
140	Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E1295-E1304.	1.8	83
141	Regulation of BCRP/ABCG2 expression by progesterone and 17 $\beta$ -estradiol in human placental BeWo cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E798-E807.	1.8	139
142	Changes in Pharmacokinetics of Anti-HIV Protease Inhibitors during Pregnancy: The Role of CYP3A and P-glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 1202-1209.	1.3	29
143	Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1). <i>Journal of Biological Chemistry</i> , 2006, 281, 16700-16706.	1.6	95
144	Electrophysiological Characterization and Modeling of the Structure Activity Relationship of the Human Concentrative Nucleoside Transporter 3 (hCNT3). <i>Molecular Pharmacology</i> , 2006, 69, 1542-1553.	1.0	48

#	ARTICLE	IF	CITATIONS
145	Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 503-514.	2.3	243
146	BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers. <i>Pharmaceutical Research</i> , 2005, 22, 2023-2034.	1.7	104
147	Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 288, C39-C45.	2.1	20
148	P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2005, 289, R963-R969.	0.9	162
149	FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N. <i>Drug Metabolism and Disposition</i> , 2005, 33, 697-705.	1.7	51
150	IDENTIFICATION OF CYTOCHROME P450 AND ARYLAMINE N-ACETYLTRANSFERASE ISOFORMS INVOLVED IN SULFADIAZINE METABOLISM. <i>Drug Metabolism and Disposition</i> , 2005, 33, 969-976.	1.7	34
151	Residues Met89 and Ser160 in the Human Equilibrative Nucleoside Transporter 1 Affect Its Affinity for Adenosine, Guanosine, S6-(4-Nitrobenzyl)-mercaptapurine Riboside, and Dipyridamole. <i>Molecular Pharmacology</i> , 2005, 67, 837-844.	1.0	36
152	Role of the breast cancer resistance protein (ABCG2) in drug transport. <i>AAPS Journal</i> , 2005, 7, E118-E133.	2.2	358
153	Placental Drug Transporters. <i>Current Drug Metabolism</i> , 2004, 5, 125-131.	0.7	106
154	HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 334-341.	1.3	200
155	Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs. <i>Journal of Biological Chemistry</i> , 2004, 279, 4490-4497.	1.6	123
156	Pharmacokinetics and Safety of Stavudine in HIV-1 Infected Pregnant Women and Their Infants: Pediatric AIDS Clinical Trials Group Protocol 332. <i>Journal of Infectious Diseases</i> , 2004, 190, 2167-2174.	1.9	36
157	Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. <i>Biochemical Pharmacology</i> , 2004, 67, 453-458.	2.0	49
158	National Institute on Drug Abuse Conference report on placental proteins, drug transport, and fetal development. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1858-1862.	0.7	13
159	The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 313-322.	2.3	15
160	The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 579-587.	2.3	16
161	Functional expression of the human breast cancer resistance protein in <i>Pichia pastoris</i> . <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 730-737.	1.0	33
162	Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptapurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. <i>Biochemical Journal</i> , 2004, 380, 131-137.	1.7	32

#	ARTICLE	IF	CITATIONS
163	Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 37711-37717.	1.6	71
164	A Single Glycine Mutation in the Equilibrative Nucleoside Transporter Gene, hENT1, Alters Nucleoside Transport Activity and Sensitivity to Nitrobenzylthioinosine. <i>Biochemistry</i> , 2002, 41, 1512-1519.	1.2	79
165	Ontogenic and longitudinal activity of Na <sup>+</sup> -nucleoside transporters in the human intestine. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G475-G481.	1.6	49
166	CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. <i>Biopharmaceutics and Drug Disposition</i> , 2001, 22, 157-168.	1.1	22
167	More collaboration needed between drug development and imaging communities. <i>Drug Discovery Today</i> , 2001, 6, 514-515.	3.2	1
168	Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na <sup>+</sup> -nucleoside transporters. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 394-402.	1.1	29
169	Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 273-278.	1.1	28
170	Pharmacokinetics of Azithromycin Administered Alone and with Atovaquone in Human Immunodeficiency Virus-Infected Children. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1516-1519.	1.4	9
171	In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 198-206.	0.7	40
172	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. , 1999, 20, 341-346.		13
173	Intestinal absorption of ribavirin is preferentially mediated by the Na <sup>+</sup> -nucleoside purine (N1) transporter. <i>Pharmaceutical Research</i> , 1998, 15, 950-952.	1.7	79
174	Functional expression of human intestinal Na <sup>+</sup> -dependent and Na <sup>+</sup> -independent nucleoside transporters in <i>Xenopus laevis</i> oocytes. <i>Biochemical Pharmacology</i> , 1997, 53, 1909-1918.	2.0	49
175	Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in <i>Macaca nemestrina</i> . <i>American Journal of Obstetrics and Gynecology</i> , 1996, 174, 856-863.	0.7	19
176	Development of a chronically catheterized maternal-fetal macaque model to study in utero mother-to-fetus HIV transmission: A preliminary report. <i>Journal of Medical Primatology</i> , 1996, 25, 218-224.	0.3	14
177	Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 332-340.	2.3	41
178	Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 556-566.	2.3	90
179	Simian Immunodeficiency Virus Infection of Macaque Primary Placental Cells. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 955-961.	0.5	4
180	Enzyme kinetic properties of human recombinant arylamine n-acetyltransferase 2 allotypic variants expressed in <i>Escherichia coli</i> . <i>Biochemical Pharmacology</i> , 1995, 50, 697-703.	2.0	55

#	ARTICLE	IF	CITATIONS
181	Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to <i>Macaca nemestrina</i> . <i>Pharmaceutical Research</i> , 1994, 11, 312-317.	1.7	20
182	Interaction of zidovudine (azidothymidine) with isoprinosine and probenecid in <i>Macaca fascicularis</i> . <i>Pharmaceutical Research</i> , 1994, 11, 181-183.	1.7	0
183	Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: In vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 427-433.	2.3	9
184	Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 528-534.	2.3	12
185	Metabolism of 3-azido-2-deoxythymidine (AZT) in human placenta trophoblasts and Hofbauer cells. <i>Biochemical Pharmacology</i> , 1994, 48, 383-389.	2.0	50
186	Maternal-fetal transfer and fetal toxicity of anti-HIV drugs. <i>Placenta</i> , 1994, 15, 67-82.	0.7	4
187	Characterization of Macaque placental trophoblast and Hofbauer cell response to Zidovudine. <i>Placenta</i> , 1994, 15, 83-95.	0.7	0
188	Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 293-302.	2.3	30
189	Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 323-328.	2.3	20
190	Effect of age on distribution of zidovudine (azidothymidine) into the cerebrospinal fluid of <i>Macaca nemestrina</i> . <i>Pharmaceutical Research</i> , 1993, 10, 1338-1340.	1.7	6
191	Transplacental pharmacokinetics of dideoxyinosine (ddI). <i>Placenta</i> , 1992, 13, A50.	0.7	0
192	Transplacental transfer and fetal toxicity of dideoxynucleosides. <i>Placenta</i> , 1992, 13, A63.	0.7	5
193	A High-Performance Liquid Chromatographic Assay for Dideoxyinosine in Monkey Plasma and Urine. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 690-691.	1.6	9
194	Pharmacokinetics of acyclovir in the term human pregnancy and neonate. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 569-576.	0.7	138
195	Disposition of drugs in cystic fibrosis. II. Hepatic blood flow. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 450-455.	2.3	13
196	Disposition of drugs in cystic fibrosis. III. Acetaminophen. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 695-701.	2.3	28
197	Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 402-409.	2.3	37
198	Age Affects the Pharmacokinetics of Inhaled Anesthetics in Humans. <i>Anesthesia and Analgesia</i> , 1991, 73, 310-318.	1.1	32

#	ARTICLE	IF	CITATIONS
199	Problems in Pharmacokinetic Investigations in Patients with HIV Infection. <i>Clinical Pharmacokinetics</i> , 1990, 19, 172-176.	1.6	11
200	Simple and effective procedure for complete urine collection from infant macaques ( <i>Macaca</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 <sub>3</sub> Tf 50 702	0.7	3
201	Dose-ranging pharmacokinetics of zidovudine (azidothymidine) in the rat. <i>Pharmaceutical Research</i> , 1989, 06, 734-736.	1.7	16
202	Clinical Pharmacokinetics of Zidovudine. <i>Clinical Pharmacokinetics</i> , 1989, 17, 1-9.	1.6	92
203	Isoflurane elimination via a bubble oxygenator during extra circulation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1988, 2, 41-44.	0.2	15
204	Bayesian calibration. <i>Analytica Chimica Acta</i> , 1986, 181, 27-36.	2.6	10
205	Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 86-93.	2.3	120
206	Pitfalls in assessing the radiopurity of tritiated steroids by high-performance liquid chromatography. <i>Journal of Chromatography A</i> , 1983, 261, 298-300.	1.8	10
207	Further Considerations of the "Single-Point Single-Dose" Method to Estimate Individual Maintenance Dosage Requirements. <i>Therapeutic Drug Monitoring</i> , 1982, 4, 201-208.	1.0	12